Xilio Therapeutics XLO
NASDAQ XLO
$8.48 +0.08 (+0.97%)
As of: Oct 22, 2026 · 12:20 PM EDT

Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026)

Updated

Xilio Therapeutics (XLO) posted Change in Receivables of $6 million for Q2 2026.

Analysis

Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Change in Receivables at Xilio Therapeutics was -$11.5 million; for FY2025, it was $5 million.

  • The Q2 2026 figure stands as the highest quarterly Change in Receivables since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,168.95 Bn 1,137.53 Bn 19.71 Bn -
2 Johnson & Johnson 642.08 Bn 560.60 Bn 17.26 Bn 1.35 Bn
3 AbbVie 500.03 Bn 473.14 Bn 12.70 Bn 1.37 Bn
4 Merck 359.04 Bn 313.42 Bn 12.21 Bn -
5 Novartis Ag 301.98 Bn 265.97 Bn 11.24 Bn -
6 Astrazeneca 267.05 Bn 240.74 Bn 12.86 Bn -
7 Amgen 241.60 Bn 197.00 Bn 7.24 Bn 1.09 Bn
8 Gilead Sciences 192.44 Bn 166.64 Bn 6.22 Bn 333.00 Mn
9 Pfizer 171.37 Bn 118.01 Bn 10.94 Bn -
10 Xilio Therapeutics 164.55 Mn -363.12 Mn - 6.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.00 Mn
Mar 31, 2026 -5.00 Mn
Dec 31, 2025 -12.50 Mn
Mar 31, 2024 30.00 Mn
API Access

Xilio Therapeutics Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=XLO&period=max&api_key=YOUR_API_KEY